Skip to main content

Table 1 Demographics and clinical characteristics

From: Association of neutrophil-to-lymphocyte ratio (NLR) with the prognosis of first attack neuromyelitis optica spectrum disorder (NMOSD): a retrospective cohort study

 

Low-NLR group

(n = 162)

High-NLR group

(n = 162)

P value

Age, years,mean ± SD

41.65 ± 16.58

45.15 ± 17.32

0.064

Male sex, no. (%)

39 (24.1%)

54 (33.3%)

0.065

Hypertension, no. (%)

18 (11.1%)

27 (16.7%)

0.148

Diabetes, no. (%)

9 (5.6%)

10 (6.2%)

0.813

Initial EDSS, median (IQR)

4 (3, 5)

4 (5, 7)

< 0.001

Initial symptoms (%)

   

Optic neuritis, no. (%)

39 (24.1%)

35 (21.6%)

0.597

Acute myelitis, no. (%)

75 (46.3%)

75 (46.3%)

–

Optic neuritis with Acute myelitis, no. (%)

16 (9.9%)

21 (13.0%)

0.382

LETM, no. (%)

  

0.062

Not tested

54 (33.3%)

50 (30.9%)

 

Yes

75 (46.3%)

90 (55.6%)

 

No

33 (20.4%)

22 (13.5%)

 

Anti-AQP4 antibody, no. (%)

  

0.337

Not tested

42 (25.9%)

11 (6.8%)

 

Negative

44 (27.2%)

47 (29.0%)

 

Positive

76 (46.9%)

104 (64.2%)

 

Corticosteroids, no. (%)

155 (95.7%)

155 (95.7%)

–

Immunoglobulins, no. (%)

14 (8.6%)

19 (11.7%)

0.358

Immunosuppressants, no. (%)

52 (32.1%)

59 (36.4%)

0.245

Blood platelet count (× 109/L), median (IQR)

214 (178,256)

227.5 (185.75, 284)

0.147

Neutrophil count (× 109/L), median (IQR)

3.2 (2.59, 4.15)

6.01 (4.45, 8.40)

< 0.001

Lymphocyte count (× 109/L), median (IQR)

2 (1.7, 2.4)

1.2 (0.86, 1.71)

< 0.001

Monocyte count (× 109/L), median (IQR)

0.45 (0.36, 0.59)

0.5 (0.34, 0.65)

0.428

NLR, median (IQR)

1.63 (1.28, 2.05)

4.28 (3.01, 6.72)

< 0.001

PLR, median (IQR)

104.63(82.54, 135.62)

182.20 (122.06, 252.75)

< 0.001

LMR, median (IQR)

4.4 (3.4, 5.53)

2.77 (1.20, 4.22)

< 0.001

Follow-up EDSS, median (IQR)

2 (2, 3)

4 (3, 6)

< 0.001

Relapse, no. (%)

33(20.4%)

104(64.2%)

< 0.001

Interval, days, median (IQR)

1311 (959, 1777)

1233 (809, 1751)

0.223

DMT, no. (%)

21(13.0%)

24(14.8%)

0.63

Azathioprine

9(5.6%)

12(7.4%)

0.498

Mycophenolate mofetil

7(4.3%)

4(2.5%)

0.357

Cyclophosphamide

2(1.2%)

3(1.9%)

1

Intravenous immunoglobulin

1(0.6%)

2(1.2%)

1

Rituximab

1(0.6%)

2(1.2%)

1

  1. EDSS Extended disability status scale, LMR Lymphocyte-to-monocyte technical ratio, NLR Neutrophil-to-lymphocyte ratio, PLR Platelet-to-lymphocyte ratio, LETM longitudinally extensive transverse myelitis, AQP4 aquaporin-4, DMT disease-modifying treatment started during the follow-up